Edition:
India

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.12USD
16 Feb 2018
Change (% chg)

$0.03 (+2.75%)
Prev Close
$1.09
Open
$1.07
Day's High
$1.14
Day's Low
$1.07
Volume
51,524
Avg. Vol
187,115
52-wk High
$2.17
52-wk Low
$0.74

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $299.88
Shares Outstanding(Mil.): 147.00
Dividend: --
Yield (%): --

Financials

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

02 Nov 2017

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

20 Oct 2017

BRIEF-Indivior says ‍durect, co sign $17.5 mln patent purchase deal

* DURECT AND INDIVIOR PLC SIGN A $17.5 MILLION PATENT PURCHASE AGREEMENT​

02 Oct 2017

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

20 Sep 2017

Earnings vs. Estimates